Carlos M Barrera1, Analia Mykietiuk2, Hristo Metev3, Mimi Floarea Nitu4, Najumuddin Karimjee5, Pablo Alexis Doreski6, Ismail Mitha7, Cristina Mihaela Tanaseanu8, Joseph McDermott Molina9, Yuri Antonovsky10, Dirkie Johanna Van Rensburg11, Brian H Rowe12, Jose Flores-Figueroa13, Barbara Rewerska14, Kay Clark15, Kara Keedy15, Amanda Sheets15, Drusilla Scott15, Gary Horwith15, Anita F Das16, Brian Jamieson15, Prabhavathi Fernandes15, David Oldach17. 1. A&L Clinical Research, Miami, FL, USA. 2. Instituto Medico Platense, La Plata, Argentina. 3. Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases, Ruse, Bulgaria. 4. Dr Victor Babes Clinical Hospital for Infectious Diseases and Pneumophthisiology, Craiova, Romania. 5. Delta County Medical Center, Houston, TX, USA. 6. Centro Medico, Buenos Aires, Argentina. 7. World Wide Clinical Trials, Benoni, South Africa. 8. St Pantelimon Emergency Clinical Hospital, Bucharest, Romania. 9. Hospital Vernaza, Guayaquil, Ecuador. 10. Medsantrud City Clinical Hospital #23, Moscow, Russia. 11. Park Medical Center, Witbank, South Africa. 12. Department of Emergency Medicine and School of Public Health, University of Alberta, Edmonton, AB, Canada. 13. JM Research, Houston, TX, USA. 14. Good Doctor Specialist Outpatient Clinics, Cracow, Poland. 15. Cempra Pharmaceuticals, Chapel Hill, NC, USA. 16. Das Consulting, San Francisco, CA, USA. 17. Cempra Pharmaceuticals, Chapel Hill, NC, USA. Electronic address: doldach@cempra.com.
Abstract
BACKGROUND:Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality, and treatment recommendations, each with specific limitations, vary globally. We aimed to compare the efficacy and safety of solithromycin, a novel macrolide, with moxifloxacin for treatment of CABP. METHODS: We did this global, double-blind, double-dummy, randomised, active-controlled, non-inferiority trial at 114 centres in North America, Latin America, Europe, and South Africa. Patients (aged ≥18 years) with clinically and radiographically confirmed pneumonia of Pneumonia Outcomes Research Team (PORT) risk class II, III, or IV were randomly assigned (1:1), via an internet-based central block randomisation procedure (block size of four), to receive either oral solithromycin (800 mg on day 1, 400 mg on days 2-5, placebo on days 6-7) or oral moxifloxacin (400 mg on days 1-7). Randomisation was stratified by geographical region, PORT risk class (II vs III or IV), and medical history of asthma or chronic obstructive pulmonary disease. The study sponsor, investigators, staff, and patients were masked to group allocation. The primary outcome was early clinical response, defined as an improvement in at least two of four symptoms (cough, chest pain, sputum production, dyspnoea) with no worsening in any symptom at 72 h after the first dose of study drug, with a 10% non-inferiority margin. The primary analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT-01756339. FINDINGS: Between Jan 3, 2013, and Sept 24, 2014, we randomly assigned 860 patients to receive solithromycin (n=426) or moxifloxacin (n=434). Patients were followed up to days 28-35 after first dose. Solithromycin was non-inferior to moxifloxacin in achievement of early clinical response: 333 (78·2%) patients had an early clinical response in the solithromycin group versus 338 (77·9%) patients in the moxifloxacin group (difference 0·29, 95% CI -5·5 to 6·1). Both drugs had a similar safety profile. 43 (10%) of 155 treatment-emergent adverse events in the solithromycin group and 54 (13%) of 154 such events in the moxifloxacin group were deemed to be related to study drug. The most common adverse events, mostly of mild severity, were gastrointestinal disorders, including diarrhoea (18 [4%] patients in the solithromycin group vs 28 [6%] patients in the moxifloxacin group), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [2%] patients in each group); and nervous system disorders, including headache (19 [4%] vs 11 [3%] patients) and dizziness (nine [2%] vs seven [2%] patients). INTERPRETATION:Oral solithromycin was non-inferior to oral moxifloxacin for treatment of patients with CABP, showing the potential to restore macrolide monotherapy for this indication. FUNDING: Cempra.
RCT Entities:
BACKGROUND: Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality, and treatment recommendations, each with specific limitations, vary globally. We aimed to compare the efficacy and safety of solithromycin, a novel macrolide, with moxifloxacin for treatment of CABP. METHODS: We did this global, double-blind, double-dummy, randomised, active-controlled, non-inferiority trial at 114 centres in North America, Latin America, Europe, and South Africa. Patients (aged ≥18 years) with clinically and radiographically confirmed pneumonia of Pneumonia Outcomes Research Team (PORT) risk class II, III, or IV were randomly assigned (1:1), via an internet-based central block randomisation procedure (block size of four), to receive either oral solithromycin (800 mg on day 1, 400 mg on days 2-5, placebo on days 6-7) or oral moxifloxacin (400 mg on days 1-7). Randomisation was stratified by geographical region, PORT risk class (II vs III or IV), and medical history of asthma or chronic obstructive pulmonary disease. The study sponsor, investigators, staff, and patients were masked to group allocation. The primary outcome was early clinical response, defined as an improvement in at least two of four symptoms (cough, chest pain, sputum production, dyspnoea) with no worsening in any symptom at 72 h after the first dose of study drug, with a 10% non-inferiority margin. The primary analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT-01756339. FINDINGS: Between Jan 3, 2013, and Sept 24, 2014, we randomly assigned 860 patients to receive solithromycin (n=426) or moxifloxacin (n=434). Patients were followed up to days 28-35 after first dose. Solithromycin was non-inferior to moxifloxacin in achievement of early clinical response: 333 (78·2%) patients had an early clinical response in the solithromycin group versus 338 (77·9%) patients in the moxifloxacin group (difference 0·29, 95% CI -5·5 to 6·1). Both drugs had a similar safety profile. 43 (10%) of 155 treatment-emergent adverse events in the solithromycin group and 54 (13%) of 154 such events in the moxifloxacin group were deemed to be related to study drug. The most common adverse events, mostly of mild severity, were gastrointestinal disorders, including diarrhoea (18 [4%] patients in the solithromycin group vs 28 [6%] patients in the moxifloxacin group), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [2%] patients in each group); and nervous system disorders, including headache (19 [4%] vs 11 [3%] patients) and dizziness (nine [2%] vs seven [2%] patients). INTERPRETATION: Oral solithromycin was non-inferior to oral moxifloxacin for treatment of patients with CABP, showing the potential to restore macrolide monotherapy for this indication. FUNDING: Cempra.
Authors: Lokesh Sharma; Ashley Losier; Thomas Tolbert; Charles S Dela Cruz; Chad R Marion Journal: Clin Chest Med Date: 2016-12-24 Impact factor: 2.878
Authors: Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Prabhavathi Fernandes; Paul G Ambrose; David R Andes Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: George G Zhanel; Erika Hartel; Heather Adam; Sheryl Zelenitsky; Michael A Zhanel; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew J Walkty; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky Journal: Drugs Date: 2016-12 Impact factor: 9.546
Authors: Christopher MacLauchlin; Stephen E Schneider; Kara Keedy; Prabhavathi Fernandes; Brian D Jamieson Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191